Nigeria, Sept. 24 -- The Gates Foundation has announced a new partnership with Indian manufacturer Hetero Labs to drive down the cost and expand access to a groundbreaking HIV prevention drug and accelerate access for millions of people in low- and middle-income countries.
The agreement, announced in New York on Wednesday, will allow Hetero Labs to produce a generic version of lenacapavir, the world's first twice-yearly injectable pre-exposure prophylaxis (PrEP), to be sold at about $40 per patient annually.
This will come after a short oral pre-treatment regimen.
"Hetero is pleased to partner with the Gates Foundation to create a pathway for the sustainable and affordable supply of lenacapavir," said Vamsi Krishna, managing director o...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.